Helix Biopharma Corp
TSX:HBP

Watchlist Manager
Helix Biopharma Corp Logo
Helix Biopharma Corp
TSX:HBP
Watchlist
Price: 2.29 CAD 5.05% Market Closed
Market Cap: 174.9m CAD

EV/EBITDA
Enterprise Value to EBITDA

-37
Current
-8.2
Median
6.3
Industry
Lower than median
Lower than industry value

Enterprise Value to EBITDA (EV/EBITDA) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s cash earnings less non-cash expenses. EBITDA can be misleading at times, especially for companies that are highly capital intensive.

EV/EBITDA
-37
=
Enterprise Value
174.8m CAD
/
EBITDA
-4.7m CAD
All Countries
Close
EBITDA Growth EV/EBITDA to Growth
CA
Helix Biopharma Corp
TSX:HBP
Average EV/EBITDA: 40.2
Negative Multiple: -37
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -194 560.6 N/A N/A
US
Abbvie Inc
NYSE:ABBV
16.6
14%
1.2
US
Amgen Inc
NASDAQ:AMGN
18.3
11%
1.7
US
Gilead Sciences Inc
NASDAQ:GILD
12.8
7%
1.8
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
23.4
16%
1.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -580.7 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
17.1
11%
1.6
AU
CSL Ltd
ASX:CSL
12.8
8%
1.6
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
162.1
N/A N/A
NL
argenx SE
XBRU:ARGX
58.8
807%
0.1

EV/EBITDA Forward Multiples

Forward EV/EBITDA multiple is a version of the EV/EBITDA ratio that uses forecasted EBITDA for the EV/EBITDA calculation. 1-Year, 2-Years, and 3-Years forwards use EBITDA forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
EV/EBITDA
N/A
2-Years Forward
EV/EBITDA
N/A
3-Years Forward
EV/EBITDA
N/A